Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection

Brett D. Shepard, Mona R. Loutfy, Janet Raboud, Frank Mandy, Colin M. Kovacs, Christina Diong, Michele Bergeron, Victoria Govan, Stacey Rizza, Jonathan B. Angel, Andrew David Badley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE:: Because effective antiretroviral therapy (ART) reduces immune activation, we hypothesize that early changes in immune activation are associated with subsequent virologic response to therapy. DESIGN:: Observational cohort study. SETTING:: Institutional HIV clinic. SUBJECTS:: Thirty-four adult HIV patients with virologic failure on their current antiretroviral regimen. INTERVENTION:: Change to salvage regimen selected by patient's physician. MAIN OUTCOME MEASURES:: Measures of immune activation at baseline and at 2, 4, 8, and 24 weeks after enrollment. Data were analyzed by proportional hazards (PH) models. RESULTS:: PH models showed that reductions between baseline and week 2 in expression of CD38 (P = 0.02) or CD95 (P = 0.02) on CD4 T cells were associated with increased likelihood of achieving virologic suppression. Kaplan-Meier analysis demonstrated that patients who had reductions within the first 2 weeks of therapy in CD4 T-cell expression of CD38 (P = 0.003) or CD95 (P = 0.08) were more likely to achieve viral suppression than those who did not. CONCLUSIONS:: Reduced CD4 T-cell expression of CD38 and CD95 occurring within 2 weeks of salvage therapy is associated with subsequent viral suppression. Monitoring CD38 and CD95 may allow earlier assessment of the response to ART.

Original languageEnglish (US)
Pages (from-to)149-155
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume48
Issue number2
DOIs
StatePublished - Jun 1 2008

Fingerprint

Salvage Therapy
HIV Infections
T-Lymphocytes
Proportional Hazards Models
HIV
Kaplan-Meier Estimate
Therapeutics
Observational Studies
Cohort Studies
Physicians

Keywords

  • Antiretroviral therapy
  • Clinical trial
  • HIV
  • Immune activation
  • Prognosis
  • Virologic failure

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Virology
  • Immunology

Cite this

Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. / Shepard, Brett D.; Loutfy, Mona R.; Raboud, Janet; Mandy, Frank; Kovacs, Colin M.; Diong, Christina; Bergeron, Michele; Govan, Victoria; Rizza, Stacey; Angel, Jonathan B.; Badley, Andrew David.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 48, No. 2, 01.06.2008, p. 149-155.

Research output: Contribution to journalArticle

Shepard, Brett D. ; Loutfy, Mona R. ; Raboud, Janet ; Mandy, Frank ; Kovacs, Colin M. ; Diong, Christina ; Bergeron, Michele ; Govan, Victoria ; Rizza, Stacey ; Angel, Jonathan B. ; Badley, Andrew David. / Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection. In: Journal of Acquired Immune Deficiency Syndromes. 2008 ; Vol. 48, No. 2. pp. 149-155.
@article{c03f219ad03744ada176f3270467d9ac,
title = "Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection",
abstract = "OBJECTIVE:: Because effective antiretroviral therapy (ART) reduces immune activation, we hypothesize that early changes in immune activation are associated with subsequent virologic response to therapy. DESIGN:: Observational cohort study. SETTING:: Institutional HIV clinic. SUBJECTS:: Thirty-four adult HIV patients with virologic failure on their current antiretroviral regimen. INTERVENTION:: Change to salvage regimen selected by patient's physician. MAIN OUTCOME MEASURES:: Measures of immune activation at baseline and at 2, 4, 8, and 24 weeks after enrollment. Data were analyzed by proportional hazards (PH) models. RESULTS:: PH models showed that reductions between baseline and week 2 in expression of CD38 (P = 0.02) or CD95 (P = 0.02) on CD4 T cells were associated with increased likelihood of achieving virologic suppression. Kaplan-Meier analysis demonstrated that patients who had reductions within the first 2 weeks of therapy in CD4 T-cell expression of CD38 (P = 0.003) or CD95 (P = 0.08) were more likely to achieve viral suppression than those who did not. CONCLUSIONS:: Reduced CD4 T-cell expression of CD38 and CD95 occurring within 2 weeks of salvage therapy is associated with subsequent viral suppression. Monitoring CD38 and CD95 may allow earlier assessment of the response to ART.",
keywords = "Antiretroviral therapy, Clinical trial, HIV, Immune activation, Prognosis, Virologic failure",
author = "Shepard, {Brett D.} and Loutfy, {Mona R.} and Janet Raboud and Frank Mandy and Kovacs, {Colin M.} and Christina Diong and Michele Bergeron and Victoria Govan and Stacey Rizza and Angel, {Jonathan B.} and Badley, {Andrew David}",
year = "2008",
month = "6",
day = "1",
doi = "10.1097/QAI.0b013e31816d9c3b",
language = "English (US)",
volume = "48",
pages = "149--155",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection

AU - Shepard, Brett D.

AU - Loutfy, Mona R.

AU - Raboud, Janet

AU - Mandy, Frank

AU - Kovacs, Colin M.

AU - Diong, Christina

AU - Bergeron, Michele

AU - Govan, Victoria

AU - Rizza, Stacey

AU - Angel, Jonathan B.

AU - Badley, Andrew David

PY - 2008/6/1

Y1 - 2008/6/1

N2 - OBJECTIVE:: Because effective antiretroviral therapy (ART) reduces immune activation, we hypothesize that early changes in immune activation are associated with subsequent virologic response to therapy. DESIGN:: Observational cohort study. SETTING:: Institutional HIV clinic. SUBJECTS:: Thirty-four adult HIV patients with virologic failure on their current antiretroviral regimen. INTERVENTION:: Change to salvage regimen selected by patient's physician. MAIN OUTCOME MEASURES:: Measures of immune activation at baseline and at 2, 4, 8, and 24 weeks after enrollment. Data were analyzed by proportional hazards (PH) models. RESULTS:: PH models showed that reductions between baseline and week 2 in expression of CD38 (P = 0.02) or CD95 (P = 0.02) on CD4 T cells were associated with increased likelihood of achieving virologic suppression. Kaplan-Meier analysis demonstrated that patients who had reductions within the first 2 weeks of therapy in CD4 T-cell expression of CD38 (P = 0.003) or CD95 (P = 0.08) were more likely to achieve viral suppression than those who did not. CONCLUSIONS:: Reduced CD4 T-cell expression of CD38 and CD95 occurring within 2 weeks of salvage therapy is associated with subsequent viral suppression. Monitoring CD38 and CD95 may allow earlier assessment of the response to ART.

AB - OBJECTIVE:: Because effective antiretroviral therapy (ART) reduces immune activation, we hypothesize that early changes in immune activation are associated with subsequent virologic response to therapy. DESIGN:: Observational cohort study. SETTING:: Institutional HIV clinic. SUBJECTS:: Thirty-four adult HIV patients with virologic failure on their current antiretroviral regimen. INTERVENTION:: Change to salvage regimen selected by patient's physician. MAIN OUTCOME MEASURES:: Measures of immune activation at baseline and at 2, 4, 8, and 24 weeks after enrollment. Data were analyzed by proportional hazards (PH) models. RESULTS:: PH models showed that reductions between baseline and week 2 in expression of CD38 (P = 0.02) or CD95 (P = 0.02) on CD4 T cells were associated with increased likelihood of achieving virologic suppression. Kaplan-Meier analysis demonstrated that patients who had reductions within the first 2 weeks of therapy in CD4 T-cell expression of CD38 (P = 0.003) or CD95 (P = 0.08) were more likely to achieve viral suppression than those who did not. CONCLUSIONS:: Reduced CD4 T-cell expression of CD38 and CD95 occurring within 2 weeks of salvage therapy is associated with subsequent viral suppression. Monitoring CD38 and CD95 may allow earlier assessment of the response to ART.

KW - Antiretroviral therapy

KW - Clinical trial

KW - HIV

KW - Immune activation

KW - Prognosis

KW - Virologic failure

UR - http://www.scopus.com/inward/record.url?scp=46449102432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46449102432&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e31816d9c3b

DO - 10.1097/QAI.0b013e31816d9c3b

M3 - Article

C2 - 18360289

AN - SCOPUS:46449102432

VL - 48

SP - 149

EP - 155

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -